[Featured Stock] NKMAX, First US FDA Approval Expected for 'Complete Remission' NK Therapy... Corporate Value Begins to Rise

[Asia Economy Reporter Hyunseok Yoo] Reevaluation of NKMAX's corporate value is ongoing. Expectations that it could be the first to receive NK therapy approval from the US FDA are leading to a rise in its stock price. Its market capitalization has surpassed 1 trillion won.

As of 10:22 AM on the 10th, NKMAX was trading at 28,900 won, up 13.33% (3,400 won) compared to the previous trading day.

Park Sang-woo, CEO of NKMAX, stated in an interview with a media outlet the day before, "By administering NK cell therapy in combination with immune checkpoint inhibitors via intravenous injection, we have achieved the world's first complete remission result in solid tumors," adding, "We aim to become the first NK cell therapy company to receive approval from the US Food and Drug Administration (FDA)."

NKMAX is developing SNK01 as a cell therapy for solid tumor patients who do not respond to existing treatments. They are discussing joint development with global pharmaceutical companies targeting solid tumor patients who cannot be treated with conventional anticancer drugs and those with a high risk of recurrence.

The biggest advantage of SNK01 is that it can be administered multiple times until the cancer cells in the patient's body completely disappear. Since it is produced as a customized treatment for each patient like CAR-T, the treatment cost is high.

This content was produced with the assistance of AI translation services.